1. Scrip

Start-Up Quarterly Statistics, Q4 2009

 
• By Deanna Kamienski

Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.

Biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $976 million in the fourth quarter of 2009, a whopping 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total Q4 09 fundraising, 66% or $640 million went to the biopharmaceutical industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). ( See Exhibit 1.)

In TheIN VIVO Blog's Second Annual Deal of the Year competition, Movetis NV's €98 million ($147 million) initial public offering was the clear winner of the Exit/Financing category. [See Deal] ( See "2009 Biopharma Deals Of The Year: Roche/Genentech, Movetis' IPO, Elan/J&J," The Pink Sheet DAILY, January 5, 2010 Also see "2009 Biopharma Deals Of The Year: Roche/Genentech, Movetis' IPO, Elan/J&J" - Pink Sheet, 5 January, 2010.,"Financings Of The Fortnight: Movetis Files First European Biopharma IPO Since Early 2008," The Pink Sheet DAILY, November 20, 2009 Also see "Financings Of The Fortnight: Movetis Files First European Biopharma IPO Since Early 2008" - Pink Sheet, 20 November, 2009., and "Financings of the Fortnight Has European Flavor, Movetis Roadshow Fever," The IN VIVO Blog, November 20, 2009 [A#3956098597741509765].) This was quite a feat for a start-up, considering the harsh economic climate that companies have had to face recently

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.